Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Passes Medical Tort Reform Bill With Protections For FDA-Approved Products

This article was originally published in The Pink Sheet Daily

Executive Summary

The HEALTH Act would subject a manufacturer to punitive damages in cases of misrepresentation, withholding of information or bribery.

You may also be interested in...



PhRMA Agenda For 2005 Includes Medicare Start-Up, Liability Reform

Trade association will work on medical malpractice issues particularly at the state level. "Access & Affordability" initiative includes support for expanding coverage to the uninsured, and continued efforts around patient assistance programs.

Sen. Frist Outlines 2004 Health Policy Goals: Uninsured, Medical Liability Reform

Senate GOP task force will present proposals to address the uninsured in six to eight weeks. Frist says leadership is flexible on malpractice award caps.

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.

Topics

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel